# Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies

Source: https://onco.cc/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/  
OnCo record `paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The largest Chinese triple-negative cohort, 465 patients from Fudan, carried more PIK3CA mutations than American tumours and sorted into four subtypes, with the luminal androgen receptor type showing HER2 mutations and CDKN2A loss.

## Summary

Clinical, genomic and transcriptomic data of 465 primary TNBCs were analysed. PIK3CA mutations and copy-number gains of chromosome 22q11 were more frequent in the Chinese cohort than in The Cancer Genome Atlas. TNBCs were classified into four transcriptome-based subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed and mesenchymal-like, with putative therapeutic targets or biomarkers identified in each. The LAR subtype showed more ERBB2 somatic mutations, infrequent mutational signature 3 and frequent CDKN2A loss.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Journal: Cancer Cell
- Year: 2019
- DOI: 10.1016/j.ccell.2019.02.001
- Authors: Jiang YZ, Ma D, Suo C, et al.
- Findings: PIK3CA mutations and 22q11 gains more frequent than in TCGA.; Four subtypes: LAR, immunomodulatory, basal-like immune-suppressed, mesenchymal-like.; LAR: more ERBB2 mutations, infrequent signature 3, frequent CDKN2A loss.
- What it means: The FUSCC cohort is the East Asian reference and the basis of the FUTURE subtype-guided umbrella trial; its LAR findings point to CDK4/6 and HER2-mutant strategies rather than PARP inhibitors for that subtype.
- Caveats: Single-institution Chinese cohort; subtype frequencies are not in the abstract and are not quoted here.; Comparison with TCGA mixes sequencing platforms.

## Sources

- Jiang et al., Cancer Cell 2019: genomic and transcriptomic landscape of 465 Chinese TNBCs (FUSCC): https://doi.org/10.1016/j.ccell.2019.02.001
- PubMed: https://pubmed.ncbi.nlm.nih.gov/30853353/

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [CDKN2A](https://onco.cc/targets/cdkn2a/), [HER2](https://onco.cc/targets/her2/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- institutions: [Zhongshan Hospital, Fudan University](https://onco.cc/institutions/zhongshan-hospital-fudan/)
- terms: [Mutational signature](https://onco.cc/terms/mutational-signature/)
- people: [Yi-Zhou Jiang](https://onco.cc/people/jiang-yi-zhou/), [Zhi-Ming Shao](https://onco.cc/people/shao-zhi-ming/)
- journals: [Cancer Cell](https://onco.cc/journals/cancer-cell/)

---
JSON: https://onco.cc/api/v1/entities/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019.json